165 related articles for article (PubMed ID: 37061372)
21. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
[TBL] [Abstract][Full Text] [Related]
22. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
[TBL] [Abstract][Full Text] [Related]
23. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
24. Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial.
Melica G; Bartolucci P; Audureau E; Le Corvoisier P; Habibi A; Gellen J; Selmane D; Michel M; Lacabaratz C; Levy Y
Clin Infect Dis; 2023 Jun; 76(11):1949-1958. PubMed ID: 36705266
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
[TBL] [Abstract][Full Text] [Related]
26. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
27. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
Buchwald UK; Andrews CP; Ervin J; Peterson JT; Tamms GM; Krupa D; Ajiboye P; Roalfe L; Krick AL; Sterling TM; Wang M; Martin JC; Stek JE; Kohn MA; Folaranmi T; Abeygunawardana C; Hartzel J; Musey LK;
Hum Vaccin Immunother; 2021 Aug; 17(8):2678-2690. PubMed ID: 34019468
[TBL] [Abstract][Full Text] [Related]
28. Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients.
Mülling N; van de Sand L; Völk K; Aufderhorst UW; van der Linden M; Horn PA; Kribben A; Wilde B; Krawczyk A; Witzke O; Lindemann M
Infection; 2023 Dec; 51(6):1703-1716. PubMed ID: 37243960
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial.
Okinaka K; Akeda Y; Inamoto Y; Fuji S; Ito A; Tanaka T; Kurosawa S; Kim SW; Tanosaki R; Yamashita T; Ohwada C; Kurata K; Mori T; Onozawa M; Takano K; Yokoyama H; Koh K; Nagafuji K; Nakayama K; Sakura T; Takahashi T; Oishi K; Fukuda T
Clin Microbiol Infect; 2023 Apr; 29(4):482-489. PubMed ID: 36503114
[TBL] [Abstract][Full Text] [Related]
31. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.
Papadatou I; Lagousi T; Kattamis A; Spoulou V
Ann Hematol; 2019 Mar; 98(3):775-779. PubMed ID: 30683996
[TBL] [Abstract][Full Text] [Related]
32. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
[TBL] [Abstract][Full Text] [Related]
33. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
35. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
Chichili GR; Smulders R; Santos V; Cywin B; Kovanda L; Van Sant C; Malinoski F; Sebastian S; Siber G; Malley R
Vaccine; 2022 Jul; 40(31):4190-4198. PubMed ID: 35690500
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
Azuma M; Oishi K; Akeda Y; Morino S; Motoki Y; Hanibuchi M; Nishioka Y
Vaccine; 2023 Jan; 41(5):1042-1049. PubMed ID: 36593171
[TBL] [Abstract][Full Text] [Related]
38. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.
Eriksson M; Käyhty H; Saha H; Lahdenkari M; Koskinen P; Mäkisalo H; Anttila VJ
Transpl Infect Dis; 2020 Aug; 22(4):e13343. PubMed ID: 32473046
[TBL] [Abstract][Full Text] [Related]
39. The safety of pneumococcal vaccines at the time of sequential schedule: data from surveillance of adverse events following 13-valent conjugated pneumococcal and 23-valent polysaccharidic pneumococcal vaccines in newborns and the elderly, in Puglia (Italy), 2013-2020.
Di Lorenzo A; Martinelli A; Bianchi FP; Scazzi FL; Diella G; Tafuri S; Stefanizzi P
Ann Ig; 2023; 35(4):459-467. PubMed ID: 36477097
[TBL] [Abstract][Full Text] [Related]
40. Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.
Sterrett S; Peng BJ; Burton RL; LaFon DC; Westfall AO; Singh S; Pride M; Anderson AS; Ippolito GC; Schroeder HW; Nahm MH; Krishna Prasad A; Goepfert P; Bansal A
Vaccine; 2020 Feb; 38(7):1778-1786. PubMed ID: 31911030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]